Jpmorgan Chase & CO Bio Atla, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Bio Atla, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,277 shares of BCAB stock, worth $957. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,277

Previous 1,129 13.11%

Holding current value

$957

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$0.28 - $0.68 $41 - $100	148 Added 13.11%	1,277 $0
Q3 2024 Dec 26, 2024	SELL	$1.17 - $2.05 $8,436 - $14,782	-7,211 Reduced 86.46%	1,129 $1,000
Q3 2024 Nov 08, 2024	SELL	$1.17 - $2.05 $8,436 - $14,782	-7,211 Reduced 86.46%	1,129 $1,000
Q2 2024 Dec 26, 2024	BUY	$1.37 - $3.92 $9,879 - $28,267	7,211 Added 638.71%	8,340 $11,000
Q2 2024 Aug 12, 2024	SELL	$1.37 - $3.92 $30,445 - $87,114	-22,223 Reduced 72.71%	8,340 $11,000
Q1 2024 Dec 26, 2024	BUY	$1.88 - $3.46 $55,335 - $101,841	29,434 Added 2607.09%	30,563 $105,000
Q1 2024 May 10, 2024	SELL	$1.88 - $3.46 $15,823 - $29,122	-8,417 Reduced 21.59%	30,563 $105,000
Q4 2023 Dec 26, 2024	BUY	$1.27 - $3.18 $48,070 - $120,366	37,851 Added 3352.61%	38,980 $95,000
Q4 2023 Feb 12, 2024	SELL	$1.27 - $3.18 $8,329 - $20,857	-6,559 Reduced 14.4%	38,980 $95,000
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $294 - $531	173 Added 0.38%	45,539 $77,000
Q2 2023 Aug 11, 2023	BUY	$2.83 - $3.87 $99,876 - $136,580	35,292 Added 350.33%	45,366 $136,000
Q1 2023 May 11, 2023	SELL	$2.3 - $8.25 $358,153 - $1.28 Million	-155,719 Reduced 93.92%	10,074 $26,000
Q4 2022 Feb 13, 2023	SELL	$6.29 - $11.01 $707,109 - $1.24 Million	-112,418 Reduced 40.41%	165,793 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $9,937 - $40,120	3,380 Added 1.23%	278,211 $2.14 Million
Q2 2022 Aug 11, 2022	BUY	$2.13 - $5.38 $550,811 - $1.39 Million	258,597 Added 1592.93%	274,831 $783,000
Q1 2022 May 11, 2022	BUY	$4.38 - $18.78 $5,461 - $23,418	1,247 Added 8.32%	16,234 $81,000
Q4 2021 Feb 10, 2022	SELL	$19.0 - $30.95 $218,671 - $356,203	-11,509 Reduced 43.44%	14,987 $295,000
Q3 2021 Nov 12, 2021	BUY	$29.44 - $43.74 $780,042 - $1.16 Million	26,496 New	26,496 $780,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

13.5M

Call Options Held

20.7K

Put Options Held

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $27.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Bio Atla, Inc. Transaction History